Literature DB >> 11744492

Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery.

J A Gollob1, M P Upton, W C DeWolf, M B Atkins.   

Abstract

Collecting duct carcinoma of the kidney is a rare and aggressive neoplasm of the distal collecting tubules for which there is no established therapy. We describe a young woman with metastatic collecting duct carcinoma who responded to Taxol/carboplatin chemotherapy with an 80% reduction in her tumor burden, including complete regression of lymph node metastases and significant shrinkage of a renal mass. She was rendered free of disease through nephrectomy and has been without a recurrence for 20 months. This suggests that Taxol/carboplatin chemotherapy and surgery should be considered for the treatment of metastatic collecting duct carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11744492     DOI: 10.1016/s0090-4295(01)01411-x

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  14 in total

1.  Metastatic collecting duct carcinoma of the kidney responded to sunitinib.

Authors:  Hideaki Miyake; Takahiro Haraguchi; Atsushi Takenaka; Masato Fujisawa
Journal:  Int J Clin Oncol       Date:  2010-08-05       Impact factor: 3.402

2.  Metastatic collecting duct carcinoma of the kidney treated with sunitinib.

Authors:  El Mehdi Tazi; Ismail Essadi; Mohamed Fadl Tazi; Youness Ahellal; Hind M'rabti; Hassan Errihani
Journal:  World J Surg Oncol       Date:  2011-07-13       Impact factor: 2.754

Review 3.  Management of Atypical Renal Cell Carcinomas.

Authors:  Bobby C Liaw; Reza Mehrazin; Charles Baker; John P Sfakianos; Che-Kai Tsao
Journal:  Curr Treat Options Oncol       Date:  2017-09-14

4.  Collecting duct carcinoma of the kidney: A case report.

Authors:  Y U Hu; Honglan Zhou; Gang Wang; Zhiming Song; Chengwu Zhao; Yuantao Wang
Journal:  Oncol Lett       Date:  2015-03-30       Impact factor: 2.967

Review 5.  Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.

Authors:  Rui-ning Zhao; Li-hong Nie; Rui Gong; Jian-zhong Wang; Romel Wazir; Liang-ren Liu; Tu-run Song; Qiang Wei
Journal:  Int Urol Nephrol       Date:  2013-05-18       Impact factor: 2.370

6.  Management of renal collecting duct carcinoma: a systematic review and the McMaster experience.

Authors:  S Dason; C Allard; A Sheridan-Jonah; J Gill; H Jamshaid; T Aziz; B Kajal; A Kapoor
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

Review 7.  Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches.

Authors:  W Marston Linehan; Ramaprasad Srinivasan; Jorge A Garcia
Journal:  Semin Oncol       Date:  2013-08       Impact factor: 4.929

Review 8.  Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.

Authors:  Panagiotis Zoumpourlis; Giannicola Genovese; Nizar M Tannir; Pavlos Msaouel
Journal:  Clin Genitourin Cancer       Date:  2020-12-02       Impact factor: 2.872

Review 9.  Chemotherapies and immunotherapies for metastatic kidney cancer.

Authors:  Yoo-Joung Ko; Michael B Atkins
Journal:  Curr Urol Rep       Date:  2005-02       Impact factor: 2.862

10.  Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.

Authors:  Michael Staehler; N Haseke; A Roosen; T Stadler; M Bader; M Siebels; A Karl; C G Stief
Journal:  Eur J Med Res       Date:  2010       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.